Safety and feasibility of long term administration of recombinant human granulocyte-colony stimulating factor in patients with amyotrophic lateral sclerosis

Cytokine

Volumn 67, Issue 1, 2014, Pages 21-28

  Grassinger, Jochen ^a   Khomenko, Andrei ^a   Hart, Christina ^a   Baldaranov, Dobri ^a   Johannesen, Siw W ^a   Mueller, Gunnar ^a   Schelker, Roland ^a   Schulte Mattler, Wilhelm ^a   Andreesen, Reinhard ^a   Bogdahn, Ulrich ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

ALS; Amyotrophic lateral sclerosis; G CSF; Granulocyte colony stimulating factor

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; NEUROPROTECTIVE AGENT; RECOMBINANT PROTEIN;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BACKACHE; BONE MARROW; BONE PAIN; CELL COUNT; CELL LOSS; CLINICAL ARTICLE; DRUG SAFETY; DYSPNEA; ERYTHROID PRECURSOR CELL; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LONG TERM CARE; MALE; MOBILIZATION; MYALGIA; PRESYNCOPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN SIZE; TREATMENT DURATION; WEAKNESS; DISEASE COURSE; DRUG EFFECTS; ERYTHROCYTE; GRANULOCYTE; LEUKOCYTE COUNT; MACROPHAGE; MIDDLE AGED; THROMBOCYTE COUNT;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; ERYTHROCYTES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HUMANS; LEUKOCYTE COUNT; MACROPHAGES; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PLATELET COUNT; RECOMBINANT PROTEINS;

EID: 84894527844     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.02.003     Document Type: Article

References (46)

1. Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009, 4:3.
2. Cheah B.C., Vucic S., Krishnan A.V., Kiernan M.C. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 2010, 17. 1942-1959.
3. Henriques A., Pitzer C., Dupuis L., Schneider A. G-CSF protects motoneurons against axotomy-induced apoptotic death in neonatal mice. BMC Neurosci 2010, 11:25.
4. Pitzer C., Krüger C., Plaas C., Kirsch F., Dittgen T., Müller R., et al. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 2008, 131:3335-3347.
5. Pollari E., Savchenko E., Jaronen M., Kanninen K., Malm T., Wojciechowski S., et al. Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 2011, 8:74.
6. Yamasaki R., Tanaka M., Fukunaga M., Tateishi T., Kikuchi H., Motomura K., et al. Restoration of microglial function by granulocyte-colony stimulating factor in ALS model mice. J Neuroimmunol 2010, 229:51-62.
7. Schneider A., Kruger C., Steigleder T., Weber D., Pitzer C., Laage R., et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005, 115:2083-2098.
8. Hao H.N., Zhao J., Thomas R.L., Parker G.C., Lyman W.D. Fetal human hematopoietic stem cells can differentiate sequentially into neural stem cells and then astrocytes in vitro. J Hematother Stem Cell Res 2003, 12:23-32.
9. +/CD34 stem/progenitor cells in a cell-to-cell contact dependent manner. Stem Cells Dev 2008, 17:1005-1016.
10. Grassinger J., Mueller G., Hart C., Nilsson S.K., Haylock D.N., Andreesen R., et al. Detection and quantification of functionally defined hematopoietic progenitor cells and tissue specific mRNA within the peripheral blood of myeloma patients after administration of granulocyte colony-stimulating factor and erythropoietin. Eur J Haematol 2008, 80:20-30.
11. Chio A., Mora G., La Bella V., Caponnetto C., Mancardi G., Sabatelli M., et al. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve 2011, 43:189-195.
12. Duning T., Schiffbauer H., Warnecke T., Mohammadi S., Floel A., Kolpatzik K., et al. G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial. PLoS One 2011, 6:e17770.
13. Tarella C., Rutella S., Gualandi F., Melazzini M., Scime R., Petrini M., et al. Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. Cytotherapy 2010, 12:50-59.
14. Nicola N.A., Metcalf D., Matsumoto M., Johnson G.R. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem 1983, 258:9017-9023.
15. Neben S., Marcus K., Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 1993, 81:1960-1967.
16. Bronchud M.H., Potter M.R., Morgenstern G., Blasco M.J., Scarffe J.H., Thatcher N., et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 1988, 58:64-69.
17. Semerad C.L., Christopher M.J., Liu F., Short B., Simmons P.J., Winkler I., et al. G-CSF potently inhibits osteoblast activity and CXCL12mRNA expression in the bone marrow. Blood 2005, 106:3020-3027.
18. Jin F., Zhai Q., Qiu L., Meng H., Zou D., Wang Y., et al. Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization. Bone Marrow Transplant 2008, 42:581-588.
19. Lévesque J., Hendy J., Takamatsu Y., Williams B., Winkler I., Simmons P. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002, 30:440-449.
20. Boxer L.A., Hutchinson R., Emerson S. Recombinant human granulocyte-colony-stimulating factor in the treatment of patients with neutropenia. Clin Immunol Immunopathol 1992, 62:S39-S46.
21. Bronchud M.H., Scarffe J.H., Thatcher N., Crowther D., Souza L.M., Alton N.K., et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987, 56:809-813.
22. Dreger P., Haferlach T., Eckstein V., Jacobs S., Suttorp M., Löffler H., et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994, 87:609-613.
23. Brooks B.R., Miller R.G., Swash M., Munsat T.L. Diseases WFoNRGoMN. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, 1:293-299.
24. + cell determination by flow cytometry. Int Soc Hematother Graft Eng J Hematother 1996, 5:213-226.
25. Hoggatt J., Pelus L.M. Mobilization of hematopoietic stem cells from the bone marrow niche to the blood compartment. Stem Cell Res Ther 2011, 2:13.
26. Shinjo K., Takeshita A., Ohnishi K., Ohno R. Granulocyte colony-stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells. Leuk Lymphoma 1997, 25:37-46.
27. + cells into the myeloid lineage. Blood 1992, 80:1405-1412.
28. Makita K., Ohta K., Mugitani A., Hagihara K., Ohta T., Yamane T., et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004, 33:661-665.
29. Hershman D., Neugut A.I., Jacobson J.S., Wang J., Tsai W.Y., McBride R., et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007, 99:196-205.
30. Tigue C.C., McKoy J.M., Evens A.M., Trifilio S.M., Tallman M.S., Bennett C.L. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007, 40:185-192.
31. Giles F.J., Koeffler H.P. Secondary myelodysplastic syndromes and leukemias. Curr Opin Hematol 1994, 1:256-260.
32. Avalos B.R., Lazaryan A., Copelan E.A. Can G-CSF cause leukemia in hematopoietic stem cell donors?. Biol Blood Marrow Transplant 2011, 17:1739-1746.
33. Deol A., Abrams J., Masood A., Al-Kadhimi Z., Abidi M.H., Ayash L., et al. Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML. Bone Marrow Transplant 2013, 48(8):1112-1116.
34. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988.
35. Dale D.C., Bolyard A.A., Aprikyan A. Cyclic neutropenia. Semin Hematol 2002, 39:89-94.
36. Tichelli A., Passweg J., Hoffmann T., Gregor M., Kühne T., Favre G., et al. Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency. Br J Haematol 1999, 106:152-158.
37. De la Rubia J., Arbona C., Del Canizo C., Arrieta R., De Arriba F., Pascual M.J., et al. Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34(+) cell yields. J Hematother Stem Cell Res 2002, 11:705-709.
38. Anderlini P., Lauppe J., Przepiorka D., Seong D., Champlin R., Körbling M. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. Br J Haematol 1997, 96:415-417.
39. Chow S., Lazo-Langner A., Ormond G., Howson-Jan K., Xenocostas A. Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation. J Clin Apher 2013.
40. Jantunen E., Kvalheim G. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol 2010, 85:463-471.
41. Christopher M.J., Link D.C. Granulocyte colony-stimulating factor induces osteoblast apoptosis and inhibits osteoblast differentiation. J Bone Miner Res 2008, 23:1765-1774.
42. Nilsson S.K., Johnston H.M., Whitty G.A., Williams B., Webb R.J., Denhardt D.T., et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005, 106:1232-1239.
43. Grassinger J., Simon M., Mueller G., Drewel D., Andreesen R., Hennemann B. Bone morphogenetic protein (BMP)-7 but not BMP-2 and BMP-4 improves maintenance of primitive peripheral blood-derived hematopoietic progenitor cells (HPC) cultured in serum-free medium supplemented with early acting cytokines. Cytokine 2007, 40:165-171.
44. Roeder I., de Haan G., Engel C., Nijhof W., Dontje B., Loeffler M. Interactions of erythropoietin, granulocyte colony-stimulating factor, stem cell factor, and interleukin-11 on murine hematopoiesis during simultaneous administration. Blood 1998, 91:3222-3229.
45. Nijhof W., De Haan G., Dontje B., Loeffler M. Effects of G-CSF on erythropoiesis. Ann N Y Acad Sci 1994, 718:312-324. [discussion 24-5].
46. Tegg E.M., Tuck D.M., Lowenthal R.M., Marsden K.A. The effect of G-CSF on the composition of human bone marrow. Clin Lab Haematol 1999, 21:265-270.